


# Supplemental Figure 4.



**Supplemental Figure 4. Characterization of the ROSMAP iNs treated with 5 nM bortezomib for 72 hours.**  
 (A) DAPI (blue) and b-tubulin III (green) immunofluorescence staining in the ROSMAP iNs treated with bortezomib or vehicle control (DMSO). Scale bar = 100 μm. (B) Bar graphs of BAX and p53 protein expressions (measured by TMT-MS) in the ROSMAP iNs treated with bortezomib or vehicle control (DMSO). Statistical analysis used unpaired t-tests; ns, not significant. (C) Western blots of pan-ubiquitinated proteins in the ROSMAP iNs treated with bortezomib or vehicle control (DMSO). The total protein level was measured by REVERT stain.